Inflammation as a therapeutic target in heart failure with preserved ejection fraction

Heart failure with preserved ejection fraction (HFpEF) accounts for around half of all cases of heart failure and may become the dominant type of heart failure in the near future. Unlike HF with reduced ejection fraction there are few evidence-based treatment strategies available. There is a signifi...

Full description

Bibliographic Details
Published in:Frontiers in Cardiovascular Medicine
Main Authors: Zhen Hui Peh, Adel Dihoum, Dana Hutton, J. Simon C. Arthur, Graham Rena, Faisel Khan, Chim C. Lang, Ify R. Mordi
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Subjects:
inflammation
heart failure
HFpEF
interleukins
cardiometabolic
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2023.1125687/full
Description
Summary:Heart failure with preserved ejection fraction (HFpEF) accounts for around half of all cases of heart failure and may become the dominant type of heart failure in the near future. Unlike HF with reduced ejection fraction there are few evidence-based treatment strategies available. There is a significant unmet need for new strategies to improve clinical outcomes in HFpEF patients. Inflammation is widely thought to play a key role in HFpEF pathophysiology and may represent a viable treatment target. In this review focusing predominantly on clinical studies, we will summarise the role of inflammation in HFpEF and discuss potential therapeutic strategies targeting inflammation.
ISSN:2297-055X

Similar Items